Tom Marjot
@tom_marjot
Followers
1K
Following
4K
Media
93
Statuses
707
Liver doctor. Academic Clinical Lecturer at University of Oxford. Interested in #MASLD, #circadian rhythms. Moving to @Inst_of_Liver @KingsCollegeLon April 2026
Oxford, England
Joined August 2020
📢Clinical Research Fellow & PhD Opportunity @Inst_of_Liver @KingsCollegeLon Recruiting to a fully funded post to complete cutting-edge MASLD research, supervised by @phil_newsome7 & myself Please share with your networks, apply, or reach out for a chat https://t.co/Rlxb8c9v5P
1
7
13
Thank you @bmj_latest for dedicating this week’s issue to liver disease and the 🌊 that is upon us. This issue: 👉Identifying liver disease in primary care 👉Global patterns of youth alcohol consumption 👉Interpreting liver blood tests @LiverTrust @BASLedu @EASLEUAffairs
Interpreting liver blood test results can be challenging. How should clinicians interpret abnormal test results? New Education article offers guidance and a visual summary #BMJInfographic
https://t.co/WjVEONERBm
0
4
23
Exciting moments from our YI Task Force meeting in Geneva!🇨🇭 We shared ideas, planned new initiatives, and strengthened our vision for the future of hepatology 🔥 Proud to support the next generation of hepatologist and liver researchers at EASL! Opportunities to join our our
0
4
16
So proud to see my colleague @DraMartaAlonsoP from our @IDIVALdecilla @HUnivValdecilla research group contributing to the EASL YI Task Force. Great news for Cantabria and for advancing research in liver diseases! (Specially cholestatic diseases 😜😜😜😜)
Exciting moments from our YI Task Force meeting in Geneva!🇨🇭 We shared ideas, planned new initiatives, and strengthened our vision for the future of hepatology 🔥 Proud to support the next generation of hepatologist and liver researchers at EASL! Opportunities to join our our
0
4
11
In acute decompensated cirrhosis and acute on chronic liver failure, vulnerability to infection is a major driver of multiorgan failure and early death. This stems from a combination of heightened systemic and intrahepatic inflammation and a progressive weakening of
0
4
7
Amazing feat this year from my superhuman pal/colleague @Drfattyliver and now again for next year. And a wonderful cause he’s running for - our liver transplant patients. Please support him and the cause ❤️ @uhbtrust @UHBCharity
It’s that time again. It’s cold, wet and my ankles still haven’t recovered from last year. Im running #londonmarathon2026 for @UHBCharity @uhbtrust for our patients undergoing #livertransplant and living with #liverdisease @EASLnews @BASLedu @AASLDtweets
0
1
5
It’s that time again. It’s cold, wet and my ankles still haven’t recovered from last year. Im running #londonmarathon2026 for @UHBCharity @uhbtrust for our patients undergoing #livertransplant and living with #liverdisease @EASLnews @BASLedu @AASLDtweets
2026tcslondonmarathon.enthuse.com
Prof. Matthew Armstrong has launched a fundraising campaign, show your support with a donation!
3
7
20
The #EASL Mentorships Programme is an extraordinary opportunity for growth, discussion and sharing scientific projects. It is the spark for a long journey. We need young researchers (basic, translational, clinical) to ensure #liver research continues to progress. @EASLedu
Last chance to polish your application for the EASL Mentorships Programme! Deadline tomorrow 23:59 CET! Read more: https://t.co/JhUXe23d6s
#LiverTwitter #LiverX
0
2
5
From #MASLD and #ALD to liver cancer and beyond, join us next week as EASL Studio discusses key studies presented at the @AASLDTweets #TLM25 🗓️Wednesady 3 Dcember | 18:00 CET 🔗 https://t.co/OEnDtFPvKG
@DebbieShawcros1 @saulkarpen @allisonkwong @NoureddinMD @FrancqueSven
0
4
6
The final @EASLnews Governing Board of 2025 in London. So many decisions packed into one day and an incredible programme of activities planned for 2026! All delivered by the #dreamteam @EASLedu
0
3
20
Tune in this Wednesday for EASL Studio, as our faculty will explore the balance between rifaximin’s benefits in hepatic encephalopathy and the global challenge of antimicrobial resistance. https://t.co/8g378Q0A0h
@DebbieShawcros1 @RajivJalan1 @vishalcpatel @JonelTrebicka
2
7
15
Great to see the main outcomes from the 2022 UK Acute Upper GI Bleeding Audit now published in Gut. Major national effort with 5141 patient and key insights on outcomes, endoscopy access and transfusion practice. Huge thanks to all collaborators. https://t.co/xGU78SKMa6
1
9
13
⏰ #EASLStudio is starting ! Join our panel to discuss "MASLD in Practice: Who to Treat, With What, and for How Long?" 👉 https://t.co/q2LECrH17w 🗣️Cyrielle Caussy, @marurinella, @phil_newsome7 & @NoureddinMD
#LiverTwitter #LiverX
0
1
5
Thrilled to share that my PhD work is now published in @Nature. Grateful to all co-authors and senior authors - an incredible team effort. Honoured to work with such talented colleagues. Onwards for #Crohns #fistula research! @QinXiao1990 @UniofOxford 🔗 https://t.co/u3W85UH7t3
12
38
312
@JHEP_Reports @VirginiaHdezGea @EASLnews @MattiasMandorf1 💊 Selection, strategies and duration of MASLD treatment Join next week's #EASLStudio as experts debate real-world challenges of treating patients with MASLD. 📅Wednesday, 19 November| 18:00 CEST 🔗 https://t.co/q2LECrH17w
#LiverX
0
3
12
🔴 We are now LIVE: discover the behind the scenes of the @JHEP_Reports publication process! 💬 Join the discussion moderated by @MattiasMandorf1, Associate Editor: https://t.co/TinrSMc9JC
@EASLnews @VirginiaHdezGea
#EASLStudio #LiverX
1
4
12
Our behemoth of a review is finally available! We detail humoral and neural communication mechanisms across the liver-brain axis in the context of chronic liver diseases and hepatic encephalopathy: https://t.co/LEN8zpOOSp.
0
1
2
Dr Kosh Agarwal presenting at the plenary at THE LIVER MEETING 2025. Great data on delta. @Inst_of_Liver @kingsmedicine @DebbieShawcros1 @AASLDtweets @AASLDPresident
0
1
11